Results 101 to 110 of about 9,813,844 (375)

Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders

Frontiers in Pharmacology
The release of intracellular DNA into the extracellular area occurs via two pathways: cell death and active secretion by cells. The DNA, which is free in the extracellular space, is commonly known as Cell-Free DNA (cfDNA).
Fancheng Liu, Fancheng Liu, Yazhen Su, Yazhen Su, Xinling Liu, Li Zhao, Li Zhao, Zewen Wu, Zewen Wu, Yang Liu, Yang Liu, Liyun Zhang, Liyun Zhang   +12 more
doaj   +1 more source

Retroperitoneal fibrosis: a case of a patient (63y/o) treated with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) [PDF]

, 2018
Retroperitoneal fibrosis (RPF), is a rare fibroinflammatory disease. The pathogenesis of RPF is still unclear and numerous theories have been reported such as environmental factors, immunologic process, genetic component, local inflammation and advanced
A. Santoro, A. Sili Scavalli, N. Galea, R. Cirocchi, R. Poscia, ROSIELLO, FRANCESCO, V. Riccieri   +6 more
core  

Thoracic duct fistula and renal transplantation [PDF]

, 1979
Thoracic duct drainage (TDD) was established for 21-115 days in 40 kidney recipients with an average removal per patient day of 4.7 1 lymph and 1.88 billion cells. Cellular and humoral immunity were depressed. TDD and immunosuppressive drugs were started
Franks, JJ, Halgrimson, CG, Iwaki, Y, Koep, LJ, McCalmon, RT, Schröter, GP, Starzl, TE, Subryan, V, Terasaki, PI, Weil, R   +9 more
core   +2 more sources

Fully Attenuated meq and pp38 Double Gene Deletion Mutant Virus Confers Superior Immunological Protection against Highly Virulent Marek’s Disease Virus Infection

, 2022
Aijun Sun, Xuyang Zhao, Xiaojing Zhu, Zhengjie Kong, Yifei Liao, Man Teng, Yongxiu Yao, Jun Luo, Venugopal Nair, Guoqing Zhuang, Gaiping Zhang   +10 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

RMD Open, 2022
Cassandra Calabrese, Elizabeth Kirchner, Alexandra Villa-Forte, Rula A Hajj-Ali, Brandon P Moss, James P Fernandez   +5 more
doaj   +1 more source

Male external genital skin disorders: a retrospective analysis from a tertiary hospital in China

Frontiers in Medicine
BackgroundMale genital dermatoses encompass a diverse range of infectious, inflammatory, and neoplastic conditions with overlapping clinical presentations, often leading to diagnostic challenges.
Yue-Tong Qian, Xiao Ma, Jing-Yi Zhang, Jia-Wei Liu, Kai Fang, Dong-Lai Ma   +5 more
doaj   +1 more source

Assessment of the effect of a protein calorie supplement on change in CD4 count among art-naïve female TB patients co-infected with HIV in Dar Es Salaam, Tanzania [PDF]

, 2017
RATIONALE: Tuberculosis and HIV infection together form a highly mortal combination. Even after the advent of highly active antiretroviral therapy (HAART) medications, management for Tuberculosis and HIV/AIDS still remains a challenge. Poor outcomes (in
Magohe, Albert Katana
core   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

A Partnership for Health: Minorities & Biomedical Research [PDF]

, 2003
The National Institute of Allergy and Infectious Diseases (NIAID) has long recognized that minority populations bear a disproportionate burden of sickness and disease in the United States.

core